| |
Baseline
|
After chemotherapy
|
After trastuzumab therapy
|
|---|
|
LVEDVI (mL/m2)
|
56.5 ± 9.9
|
55.9 ± 10.2
|
55.7 ± 10.3
|
|
LVESVI (mL/m2)
|
20.3 ± 4.6
|
20.0 ± 5.1
|
20.2 ± 5.7
|
|
LVEF (%)
|
63.9 ± 5.9
|
64.2 ± 6.7
|
63.8 ± 7.3
|
|
LVGLS (%)
|
−22.2 ± 2.2
|
−20.2 ± 2.2*
|
−17.8 ± 2.3†‡
|
|
E (cm/sec)
|
62.7 ± 7.7
|
61.4 ± 11.6
|
59.2 ± 11.8
|
|
e’ (cm/sec)
|
8.3 ± 1.8
|
8.3 ± 1.7
|
7.9 ± 1.7
|
|
s’ (cm/sec)
|
7.4 ± 1.0
|
7.3 ± 1.0
|
7.3 ± 1.1
|
|
E/e’
|
7.7 ± 1.2
|
7.6 ± 1.5
|
7.7 ± 1.8
|
|
LAVI (mL/m2)
|
26.0 ± 3.9
|
26.1 ± 4.1
|
26.7 ± 4.0
|
|
PALS (%)
|
33.8 ± 5.6
|
30.9 ± 5.7*
|
28.0 ± 6.0†‡
|
|
LA conduit strain (%)
|
19.8 ± 3.3
|
16.6 ± 3.0*
|
15.0 ± 3.2†‡
|
|
LA booster strain (%)
|
14.0 ± 2.3
|
14.3 ± 2.7
|
13.0 ± 2.8†‡
|
|
RVSP (mmHg)
|
32.0 ± 7.3
|
30.8 ± 7.7
|
29.2 ± 8.1
|
- LVEDVI left ventricular end-diastolic volume index, LVESVI left ventricular end-systolic volume index, LVEF left ventricular ejection fraction, LVGLS left ventricular global longitudinal strain, E: early diastolic mitral inflow velocity, e’: early diastolic velocity of mitral septal annulus, s’: systolic velocity of mitral septal annulus, LAVI left atrial volume index, PALS peak atrial longitudinal strain, LA left atrium, RVSP right ventricular systolic pressure. *: p < 0.05 between baseline and after chemotherapy, †: p < 0.05 between after chemotherapy and after trastuzumab therapy, ‡: p < 0.05 between baseline and after trastuzumab therapy
